Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 19

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 19
---
 increased expenses, or when,
or if, we will be able to achieve or maintain profitability.

Even if this offering is successful, we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.

As of September 29, 2025,
June 30, 2025 and December 31, 2024, our cash and cash equivalents were approximately $0.1 million, $0.2 million and $0.2 million, respectively,
and as of June 30, 2025 and December 31, 2024, we had a negative working capital of approximately $9.2 million and $6.0 million, respectively,
and an accumulated deficit of approximately $45.3 million and $42.1 million, respectively. Based on our current plans, we believe that
our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements
through October 2025 without giving effect to the proceeds from this offering. Even if this offering is completed, we expect that we
will require substantial additional capital to commercialize our Gelrin hydrogel platform and any future product candidates. In addition,
our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds
sooner than planned. Our future funding requirements will depend on many factors, including but not limited to:

| ● | the progress, results and                                             
 costs of our ongoing and planned studies and pivotal clinical trials; |

| ● | the cost, timing and outcomes                                                           
 of regulatory review of our Gelrin hydrogel platform and any future product candidates; |

<div align='center'>17</div>

| ● | the costs of manufacturing                                                                  
 product candidates, including costs related to engaging third-party manufacturers therefor; |

| ● | the scope, progress, results                                                                                                        
 and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other 
 product candidates that we may develop or otherwise obtain in the future;                                                           |

| ● | the cost of our future                                                                                                                    
 activities, including establishing sales, marketing and distribution capabilities for any product or product candidates in any particular 
 geography where we receive marketing approval for such product candidates;                                                                |

| ● | the terms and timing of